title: Neuropathic pain in a cancer patient responding to subcutaneously administered lignocaine.
abstract: OBJECTIVE
  To demonstrate difficulties encountered in alleviating neuropathic pain in a terminally ill cancer patient, with the very tentative diagnosis of postherpetic neuralgia.
  
  
  METHODS
  A multidisciplinary pain department in a university hospital.
  
  
  METHODS
  A patient with Hodgkin's lymphoma and leiomyosarcoma in the liver developed an unusual manifestation of neuropathic pain.
  
  
  METHODS
  Oral drug treatment with morphine associated with amitriptyline, valproic acid, mexilitine, flufenazine, and methylprednisolone failed to suppress pain attacks. Only the subcutaneous instillation of lidocaine (2 mg/kg/h) could partially suppress pain. A dorsal root entry zone lesion intervention could only temporary stop the pain attacks. Infiltration and nervous stimulation techniques were not helpful.
  
  
  METHODS
  In determining pain control, the visual analog scale rating scale and the number of attacks per hour were considered.
  
  
  RESULTS
  Only the subcutaneous administration of lignocaine could partially suppress pain. Because of the patient's poor hepatic circulation, variable lidocaine plasma concentrations were responsible for intolerable side effects.
  
  
  CONCLUSIONS
  Subcutaneous lignocaine administration remains a useful method in treating neuropathic cancer pain. The poor metabolic condition of the patient can lead to deleterious high plasma levels. A dorsal root entry zone lesion could only temporarily stop the pain.
authors.affiliation: Department of Anesthesia-Section Pain Clinic, University Hospital Gent, Belgium.
authors.forename: J E
authors.initials: JE
authors.lastname: Devulder
authors.forename: L
authors.initials: L
authors.lastname: Ghys
authors.forename: W
authors.initials: W
authors.lastname: Dhondt
authors.forename: G
authors.initials: G
authors.lastname: Rolly
mesh_terms: D000328:Adult; D015360:Analgesia, Epidural; D001340:Autonomic Nerve Block; D005071:Evoked Potentials / Q000502:physiology; D006689:Hodgkin Disease / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D007279:Injections, Subcutaneous; D007890:Leiomyosarcoma / Q000150:complications* / Q000503:physiopathology; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008102:Liver Circulation; D008113:Liver Neoplasms / Q000150:complications* / Q000503:physiopathology; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D013233:Stellate Ganglion; D016896:Treatment Outcome
chemical_list: D008012:Lidocaine